Refine your search
Collections
Co-Authors
Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Twombley, Katherine
- Recent Advances in the Diagnosis and Treatment of Antibody Mediated Injury in Pediatric Kidney Transplants
Abstract Views :248 |
PDF Views:0
Authors
Affiliations
1 Department of Internal Medicine, Medical University of South Carolina 96 Jonathan Lucas Street 428 CSB, MSC 608 Charleston, SC 29435, US
2 Department of Pediatrics, Medical University of South Carolina 96 Jonathan Lucas Street 428 CSB, MSC 608 Charleston, SC 29435, US
3 Department of Internal Medicine Medical University of South Carolina 96 Jonathan Lucas Street 428 CSB, MSC 608 Charleston, SC 29435, US
4 Department of Pediatrics Medical University of South Carolina 96 Jonathan Lucas Street 428 CSB, MSC 608 Charleston, SC 29435, US
1 Department of Internal Medicine, Medical University of South Carolina 96 Jonathan Lucas Street 428 CSB, MSC 608 Charleston, SC 29435, US
2 Department of Pediatrics, Medical University of South Carolina 96 Jonathan Lucas Street 428 CSB, MSC 608 Charleston, SC 29435, US
3 Department of Internal Medicine Medical University of South Carolina 96 Jonathan Lucas Street 428 CSB, MSC 608 Charleston, SC 29435, US
4 Department of Pediatrics Medical University of South Carolina 96 Jonathan Lucas Street 428 CSB, MSC 608 Charleston, SC 29435, US
Source
Journal of Clinical Pediatric Nephrology, Vol 2, No 2 (2013), Pagination: 19-28Abstract
Antibody mediated rejection (AMR) is potentially devastating to a transplanted kidney, and can be challenging to diagnose without reliable pathology and immunology and even more challenging to treat. There is not much data on pediatric kidney transplants patients with AMR in the literature. The optimal therapy for AMR is not well defined in children or adults, but newer therapies are emerging. Our ultimate goal is preventing AMR, but until we meet that goal, we will continue to look for the safest and most efficacious therapies. Here we review the literature on the newest techniques available to help with the diagnosis of AMR and the available and emerging therapeutic options.Keywords
Antibody, Kidney, Rejection, Transplant, Treatment
References
- Mengel M, Sis B, Haas M, et al. 2012. Banff 2011 Meeting report: New concepts in antibody-mediated rejection. Am J Transplant 12:563-70.
- Solez K, Colvin RB, Racusen LC, et al. 2008. Banff 07 classification of renal allograft pathology: Updates and future directions. Am J Transplant 8:753-60.
- Solez K, Racusen LC. 2013. The Banff classification revisited. Kidney Int 83:201-6.
- Howell WM, Carter V, Clark B. 2010. The HLA system: Immunobiology, HLA typing, antibody screening and crossmatching techniques. J Clin Pathol 63:387-90.
- Fuggle SV, Martin S. 2008. Tools for human leukocyte antigen antibody detection and their application to transplanting sensitized patients. Transplantation 86:384-90.
- Tait BD, Susal C, Gebel HM, et al. 2013. Consensus Guidelines on the Testing and Clinical Management Issues Associated With HLA and Non-HLA Antibodies in Transplantation. Transplantation 95:19-47.
- Marfo K, Lu A, Ling M, Akalin E. 2011. Desensitization protocols and their outcome. Clin J Am Soc Nephrol 6:922-36.
- Claas FH. 2010. Clinical relevance of circulating donor-specific HLA antibodies. Curr Opin Organ Transplant 15:462-6.
- Everly MJ, Rebellato LM, Haisch CE, et al. 2013. Incidence and impact of de novo donor-specific alloantibody in primary renal allografts. Transplantation 95:410-7.
- Lawrence C, Willicombe M, Brookes PA, et al. 2013. Preformed complement-activating low-level donor-specific antibody predicts early antibody-mediated rejection in renal allografts. Transplantation 95:341-6.
- Wu P, Jin J, Everly MJ, Lin C, Terasaki PI, Chen J. 2013. Impact of alloantibody strength in crossmatch negative DSA positive kidney transplantation. Clin Biochem.
- Kanter Berga J, Pallardo Mateu LM, Beltran Catalan S, et al. 2011. Donor-specific HLA antibodies: Risk factors and outcomes after kidney transplantation. Transplant Proc 43:2154-6.
- Haas M. 2012. Pathology of C4d-negative antibody-mediated rejection in renal allografts. Curr Opin Organ Transplant.
- Li L, Chang A, Naesens M, et al. 2009. Steroid-free immunosuppression since 1999: 129 pediatric renal transplants with sustained graft and patient benefits. Am J Transplant 9:1362- 72.
- Chaudhuri A, Ozawa M, Everly MJ, et al. 2013. The clinical impact of humoral immunity in pediatric renal transplantation. J Am Soc Nephrol 24:655-64.
- Ginevri F, Nocera A, Comoli P, et al. 2012. Post-transplant de novo donor-specific HLA antibodies identify pediatric kidney recipients at risk for late antibody-mediated rejection. Am J Transplant 12:3355-62.
- Cohen D, Colvin RB, Daha MR, et al. 2012. Pros and cons for C4d as a biomarker. Kidney Int 81:628-39.
- Loupy A, Hill GS, Jordan SC. 2012. The impact of donor-specific anti-HLA antibodies on late kidney allograft failure. Nat Rev Nephrol 8:348-57.
- Haas M. 2010. The significance of C4d staining with minimal histologic abnormalities. Curr Opin Organ Transplant 15:21-7.
- Haas M. 2012. Pathologic features of antibody-mediated rejection in renal allografts: An expanding spectrum. Curr Opin Nephrol Hypertens 21:264-71.
- Loupy A, Hill GS, Suberbielle C, et al. 2011. Significance of C4d Banff scores in early protocol biopsies of kidney transplant recipients with preformed donor-specific antibodies (DSA). Am J Transplant 11:56-65.
- Verghese P, Dunn T, Najafian B, Kim Y, Matas A. 2013. The impact of C4d and microvascular inflammation before we knew them. Clin Transplant 27:388-96.
- de Kort H, Willicombe M, Brookes P, et al. 2013. Microcirculation inflammation associates with outcome in renal transplant patients with de novo donor-specific antibodies. Am J Transplant 13:485- 92.
- Birk PE. 2012. Surveillance biopsies in children post-kidney transplant. Pediatr Nephrol 27:753-60.
- Birk PE. 2009. What do we need to do to make protocol biopsies standard of care or should we discontinue doing? Pediatr Transplant 13:797-801.
- Birk PE, Stannard KM, Konrad HB, et al. 2004. Surveillance biopsies are superior to functional studies for the diagnosis of acute and chronic renal allograft pathology in children. Pediatr Transplant 8:29-38.
- Soulillou JP, Guyot C, Guimbretiere J, et al. 1983. Plasma exchange in early kidney graft rejection associated with anti-donor antibodies. Nephron 35:158-62.
- Bayry J, Lacroix-Desmazes S, Carbonneil C, et al. 2003. Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. Blood 101:758-65.
- Abe J, Jibiki T, Noma S, Nakajima T, Saito H, Terai M. 2005. Gene expression profiling of the effect of high-dose intravenous Ig in patients with Kawasaki disease. J Immunol 174:5837-45.
- Jordan SC, Toyoda M, Vo AA. 2009. Intravenous immunoglobulin a natural regulator of immunity and inflammation. Transplantation 88:1-6.
- Jordan SC, Quartel AW, Czer LS, et al. 1998. Post-transplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action. Transplantation 66:800-5.
- Glotz D, Antoine C, Julia P, et al. 2002. Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulins (IVIg). Am J Transplant 2:758-60.
- Montgomery RA, Zachary AA, Racusen LC, et al. 2000. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-matchpositive recipients. Transplantation 70:887-95.
- Warren DS, Zachary AA, Sonnenday CJ, et al. 2004. Successful renal transplantation across simultaneous ABO incompatible and positive crossmatch barriers. Am J Transplant 4:561-8.
- Zand MS. 2006. B-cell activity of polyclonal antithymocyte globulins. Transplantation 82:1387-95.
- Zand MS, Vo T, Huggins J, et al. 2005. Polyclonal rabbit antithymocyte globulin triggers B-cell and plasma cell apoptosis by multiple pathways. Transplantation 79:1507-15.
- Zand MS, Vo T, Pellegrin T, et al. 2006. Apoptosis and complementmediated lysis of myeloma cells by polyclonal rabbit antithymocyte globulin. Blood 107:2895-903.
- Akashi K, Richie LI, Miyamoto T, Carr WH, Weissman IL. 2000. B lymphopoiesis in the thymus. J Immunol 164:5221-6.
- Feng X, Kajigaya S, Solomou EE, et al. 2008. Rabbit ATG but not horse ATG promotes expansion of functional CD4+CD25highFOXP3+ regulatory T cells in vitro. Blood 111:3675- 83.
- Lopez M, Clarkson MR, Albin M, Sayegh MH, Najafian N. 2006. A novel mechanism of action for anti-thymocyte globulin: Induction of CD4+CD25+Foxp3+ regulatory T cells. J Am Soc Nephrol 17:2844-53.
- Sewgobind VD, Kho MM, van der Laan LJ, et al. 2009. The effect of rabbit anti-thymocyte globulin induction therapy on regulatory T cells in kidney transplant patients. Nephrol Dial Transplant 24:1635-44.
- LaCorcia G, Swistak M, Lawendowski C, et al. 2009. Polyclonal rabbit antithymocyte globulin exhibits consistent immunosuppressive capabilities beyond cell depletion. Transplantation 87:966-74.
- Bonnefoy-Berard N, Genestier L, Flacher M, et al. 1994. Apoptosis induced by polyclonal anti-lymphocyte globulins in human B-cell lines. Blood 83:1051-9.
- Furth S, Neu AM, Hart J, Zachary A, Colombani P, Fivush BA. 1999. Plasmapheresis, intravenous cytomegalovirus-specific immunoglobulin and reversal of antibody-mediated rejection in a pediatric renal transplant recipient: A case report. Pediatr Transplant 3:146-9.
- Shah A, Nadasdy T, Arend L, et al. 2004. Treatment of C4dpositive acute humoral rejection with plasmapheresis and rabbit polyclonal anti-thymocyte globulin. Transplantation 77:1399-405.
- Loken MR, Shah VO, Dattilio KL, Civin CI. 1987. Flow cytometric analysis of human bone marrow. II. Normal B lymphocyte development. Blood 70:1316-24.
- Zarkhin V, Lovelace PA, Li L, Hsieh SC, Sarwal MM. 2011. Phenotypic evaluation of B-cell subsets after rituximab for treatment of acute renal allograft rejection in pediatric recipients. Transplantation 91:1010-8.
- Twombley K, Pokala H, Ardura MI, et al. 2012. Intraventricular rituximab and systemic chemotherapy for treatment of central nervous system post-transplant lymphoproliferative disorder after kidney transplantation. Pediatr Transplant 16:E201-9.
- Faguer S, Kamar N, Guilbeaud-Frugier C, et al. 2007. Rituximab therapy for acute humoral rejection after kidney transplantation. Transplantation 83:1277-80.
- Becker YT, Becker BN, Pirsch JD, Sollinger HW. 2004. Rituximab as treatment for refractory kidney transplant rejection. Am J Transplant 4:996-1001.
- Alausa M, Almagro U, Siddiqi N, Zuiderweg R, Medipalli R, Hariharan S. 2005. Refractory acute kidney transplant rejection with CD20 graft infiltrates and successful therapy with rituximab. Clin Transplant 19:137-40.
- Lehnhardt A, Mengel M, Pape L, Ehrich JH, Offner G, Strehlau J. 2006. Nodular B-cell aggregates associated with treatment refractory renal transplant rejection resolved by rituximab. Am J Transplant 6:847-51.
- Kranz B, Kelsch R, Kuwertz-Broking E, Brocker V, Wolters HH, Konrad M. 2011. Acute antibody-mediated rejection in paediatric renal transplant recipients. Pediatr Nephrol 26:1149-56.
- Pescovitz MD. 2006. Rituximab, an anti-cd20 monoclonal antibody: History and mechanism of action. Am J Transplant 6:859-66.
- Reff ME, Carner K, Chambers KS, et al. 1994. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83:435-45.
- Billing H, Rieger S, Ovens J, et al. 2008. Successful treatment of chronic antibody-mediated rejection with IVIG and rituximab in pediatric renal transplant recipients. Transplantation 86:1214- 21.
- Billing H, Rieger S, Susal C, et al. 2012. IVIG and rituximab for treatment of chronic antibody-mediated rejection: A prospective study in paediatric renal transplantation with a 2-year follow-up. Transpl Int 25:1165-73.
- Blink EJ, Light A, Kallies A, Nutt SL, Hodgkin PD, Tarlinton DM. 2005. Early appearance of germinal center-derived memory B cells and plasma cells in blood after primary immunization. J Exp Med 201:545-54.
- Odendahl M, Mei H, Hoyer BF, et al. 2005. Generation of migratory antigen-specific plasma blasts and mobilization of resident plasma cells in a secondary immune response. Blood 105:1614-21.
- Gass JN, Gunn KE, Sriburi R, Brewer JW. 2004. Stressed-out B cells? Plasma-cell differentiation and the unfolded protein response. Trends Immunol 25:17-24.
- Kim R, Emi M, Tanabe K, Murakami S. 2006. Role of the unfolded protein response in cell death. Apoptosis 11:5-13.
- Everly MJ, Everly JJ, Susskind B, et al. 2008. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation 86:1754-61.
- Lucas JG, Co JP, Nwaogwugwu UT, Dosani I, Sureshkumar KK. 2011. Antibody-mediated rejection in kidney transplantation: An update. Expert Opin Pharmacother 12:579-92.
- Nigos JG, Arora S, Nath P, et al. 2012. Treatment of antibodymediated rejection in kidney transplant recipients: A single-center experience with a bortezomib-based regimen. Exp Clin Transplant 10:609-13.
- Sureshkumar KK, Hussain SM, Marcus RJ, et al. 2012. Proteasome inhibition with bortezomib: An effective therapy for severe antibody mediated rejection after renal transplantation. Clin Nephrol 77:246- 53.
- Walsh RC, Alloway RR, Girnita AL, Woodle ES. 2012. Proteasome inhibitor-based therapy for antibody-mediated rejection. Kidney Int 81:1067-74.
- Sberro-Soussan R, Zuberl J, Suberbielle-Boissel C, Legendre C. 2010. Bortezomib alone fails to decrease donor specific anti- HLA antibodies: Even after one year post-treatment. Clin Transpl 409-14.
- Trivedi HL, Terasaki PI, Feroz A, et al. 2009. Abrogation of anti- HLA antibodies via proteasome inhibition. Transplantation 87:1555-61.
- Everly MJ, Everly JJ, Susskind B, et al. 2009. Proteasome inhibition reduces donor-specific antibody levels. Transplant Proc 41:105- 7.
- Morrow WR, Frazier EA, Mahle WT, et al. 2012. Rapid reduction in donor-specific anti-human leukocyte antigen antibodies and reversal of antibody-mediated rejection with bortezomib in pediatric heart transplant patients. Transplantation 93:319-24.
- Twombley K, Thach L, Ribeiro A, Joseph C, Seikaly M. 2013. Acute antibody-mediated rejection in pediatric kidney transplants: A single center experience. Pediatr Transplant.
- Rother RP, Rollins SA, Mojcik CF, Brodsky RA, Bell L. 2007. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol 25:1256-64.
- Nester C, Stewart Z, Myers D, et al. 2011. Pre-emptive eculizumab and plasmapheresis for renal transplant in atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 6:1488-94.
- Weitz M, Amon O, Bassler D, Koenigsrainer A, Nadalin S. 2011. Prophylactic eculizumab prior to kidney transplantation for atypical hemolytic uremic syndrome. Pediatr Nephrol 26:1325-9.
- Stegall MD, Diwan T, Raghavaiah S, et al. 2011. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplan 11:2405- 13.
- Hughes PD, Cohney SJ. 2011. Modifiers of complement activation for prevention of antibody-mediated injury to allografts. Curr Opin Organ Transplant 16:425-33.
- Hagenbeek A, Gadeberg O, Johnson P, et al. 2008. First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: Results of a phase 1/2 trial. Blood 111:5486-95.
- Morschhauser F, Marlton P, Vitolo U, et al. 2010. Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma. Ann Oncol 21:1870-6.
- Ostergaard M, Baslund B, Rigby W, et al. 2010. Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more diseasemodifying anti-rheumatic drugs: Results of a randomized, doubleblind, placebo-controlled, phase I/II study. Arthritis Rheum 62:2227-38.
- Genovese MC, Kaine JL, Lowenstein MB, et al. 2008. Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I/II randomized, blinded, placebo-controlled, dose-ranging study. Arthritis Rheum 58:2652- 61.
- Reddy V, Jayne D, Close D, Isenberg D. 2013. B-cell depletion in SLE: Clinical and trial experience with rituximab and ocrelizumab and implications for study design. Arthritis Res Ther 15 Suppl 1:S2.
- Chaudhuri A. 2012. Ocrelizumab in multiple sclerosis: Risks and benefits. Lancet 379:1196-7; author reply 7.
- Tak PP, Mease PJ, Genovese MC, et al. 2012. Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to at least one tumor necrosis factor inhibitor: Results of a forty-eight-week randomized, double-blind, placebocontrolled, parallel-group phase III trial. Arthritis Rheum 64:360- 70.
- Stohl W, Gomez-Reino J, Olech E, et al. 2012. Safety and efficacy of ocrelizumab in combination with methotrexate in MTX-naive subjects with rheumatoid arthritis: The phase III FILM trial. Ann Rheum Dis 71:1289-96.
- Taylor PC, Quattrocchi E, Mallett S, Kurrasch R, Petersen J, Chang DJ. 2011. Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: A randomised, doubleblind, placebo-controlled clinical trial. Ann Rheum Dis 70:2119- 25.
- Leonard JP, Coleman M, Ketas JC, et al. 2003. Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non- Hodgkin’s lymphoma. J Clin Oncol 21: 3051-9.
- Steinfeld SD, Youinou P. 2006. Epratuzumab (humanised anti- CD22 antibody) in autoimmune diseases. Expert Opin Biol Ther 6:943-9.
- de Vries JF, Zwaan CM, De Bie M, et al. 2012. The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells. Leukemia 26:255-64.
- Chugh PK, Kalra BS. 2013. Belimumab: Targeted therapy for lupus. Int J Rheum Dis 16:4-13.
- Schneider P. 2005. The role of APRIL and BAFF in lymphocyte activation. Curr Opin Immunol 17:282-9.
- Stohl W. 2012. Biologic differences between various inhibitors of the BLyS/BAFF pathway: Should we expect differences between belimumab and other inhibitors in development? Curr Rheumatol Rep 14:303-9.
- Tillou X, Poirier N, Le Bas-Bernardet S, et al. 2010. Recombinant human C1-inhibitor prevents acute antibody-mediated rejection in alloimmunized baboons. Kidney Int 78:152-9.
- Walsh RC, Everly JJ, Brailey P, et al. 2010. Proteasome inhibitorbased primary therapy for antibody-mediated renal allograft rejection. Transplantation 89:277-84.
- An Unusual Case of Hodgkin's PTLD more than 10 Years after Kidney Transplantation in a Child
Abstract Views :267 |
PDF Views:0
Authors
Hawazen Alsaedi
1,
Rebecca Cafiero
1,
Sarah A Brooks
2,
Sally Self
2,
Michelle P Hudspeth
1,
Katherine Twombley
3
Affiliations
1 Department of Pediatrics, Division of Oncology, Medical University of South Carolina, SC, US
2 Department of Pathology, Medical University of South Carolina, SC, US
3 Department of Pediatrics Medical University of South Carolina 96 Jonathan Lucas Street 428 CSB, MSC 608 Charleston, SC 29435, US
1 Department of Pediatrics, Division of Oncology, Medical University of South Carolina, SC, US
2 Department of Pathology, Medical University of South Carolina, SC, US
3 Department of Pediatrics Medical University of South Carolina 96 Jonathan Lucas Street 428 CSB, MSC 608 Charleston, SC 29435, US
Source
Journal of Clinical Pediatric Nephrology, Vol 2, No 2 (2013), Pagination: 50-54Abstract
PTLD (post-transplant lymphoproliferative disorder) is a serious complication of immunosuppression seen in patients after solid organ and bone marrow transplantation. The overall incidence of PTLD in children as reported by the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS) is 1.2%, and the incidence of Hodgkin lymphoma (HL) is even rarer. The Epstein-Barr virus plays an important role in the pathogenesis of post-transplant lymphomas because of its ability to transform infected cells. Differentiating PTLD from malignant lymphomas, especially HL can be challenging, but it is vitally necessary as the treatments differ greatly.Keywords
Kidney, Post-transplant Lymphoproliferative Disorder, Transplant, HodgkinReferences
- Dharnidharka VR, Sullivan EK, Stablein DM, Tejani AH, Harmon WE, 2001. Risk factors for post-transplant lymphoproliferative disorder (PTLD) in pediatric kidney transplantation: A report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Transplantation 71:1065-8.
- Twombley K, Pokala H, Ardura MI, et al., 2012. Intraventricular rituximab and systemic chemotherapy for treatment of central nervous system post-transplant lymphoproliferative disorder after kidney transplantation. Pediatr Transplant 16:E201-9.
- Schober T, Framke T, Kreipe H, et al., 2013. Character-istics of early and late PTLD development in pediatric solid organ transplant recipients. Transplantation 95:240-6.
- Schwartz CL, Constine LS, Villaluna D, et al., 2009. A riskadapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: The results of P9425. Blood 114:2051-9.
- Birk PE, Stannard KM, Konrad HB, et al., 2004. Surveillance biopsies are superior to functional studies for the diagnosis of acute and chronic renal allograft pathology in children. Pediatr Transplant 8:29-38.
- Vegso G, Hajdu M, Sebestyen A, 2011. Lymphoproliferative disorders after solid organ transplantation—classifi-cation, incidence, risk factors, early detection and treatment options. Pathol Oncol Res 17:443-54.
- Dharnidharka VR, Douglas VK, Hunger SP, Fennell RS, 2004. Hodgkin’s lymphoma after post-transplant lymphoproliferative disease in a renal transplant recipient. Pediatr Transplant 8:87- 90.
- Rohr JC, Wagner HJ, Lauten M, et al., 2008. Differentiation of EBV-induced post-transplant Hodgkin lymphoma from Hodgkinlike post-transplant lymphoproliferative disease. Pediatr Transplant 12:426-31.
- Goyal RK, McEvoy L, Wilson DB, 1996. Hodgkin disease after renal transplantation in childhood. J Pediatr Hematol Oncol 18:392-5.
- Bierman PJ, Vose JM, Langnas AN, et al., 1996. Hodgkin’s disease following solid organ transplantation. Ann Oncol 7:265- 70.
- Nalesnik MA, Randhawa P, Demetris AJ, Casavilla A, Fung JJ, Locker J, 1993. Lymphoma resembling Hodgkin disease after post-transplant lymphoproliferative disorder in a liver transplant recipient. Cancer 72:2568-73.
- Kauffman HM, Cherikh WS, Cheng Y, Hanto DW, Kahan BD, 2005. Maintenance immunosuppression with target-ofrapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 80:883-9.
- Campistol JM, Eris J, Oberbauer R, et al., 2006. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol 17:581-9.
- Alberu J, Pascoe MD, Campistol JM, et al., 2011. Lower malignancy rates in renal allograft recipients converted to sirolimus-based, calcineurin inhibitor-free immunotherapy: 24- month results from the CONVERT trial. Transplantation 92:303- 10.
- Degi A, Kerti A, Kis E, et al., 2012. Cardiovascular risk assessment in children following kidney transplantation. Pediatr Transplant 16:564-76.
- Mitsnefes MM, 2012. Cardiovascular disease in children with chronic kidney disease. J Am Soc Nephrol 23:578-85.